A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu-Positive Breast CancerKurian, A. W.; Thompson, R. N.; Gaw, A. F.; Arai, S.; Ortiz, R.; Garber, A. M. · Journal of Clinical Oncology · 2007

PCN81 A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/NEU-Positive Breast Cancer in ColombiaBuendia rodriguez, J.A.; Vallejos, C. · Value in Health · 2011

Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancerLe, Quang A.; Bae, Yuna H.; Kang, Jenny H. · Breast Cancer Research and Treatment · 2016

LBA12_PRPERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis resultsHulme, C; Hall, P; Shinkins, B; Chehadah, F; McCabe, C; Hiller, L; Dunn, J; Earl, H M · Annals of Oncology · 2018

A cost-effectiveness analysis of Herceptin® (trastuzumab) in combination with Paclitaxel as a first line treatment for HER2 positive (3+) Metastatic Breast Cancer (MBC) patients in the UKA. Ratcliffe; C. Poole; D. Miles · 2001

Computer model accurately predicts chemotherapy responseInpharma Weekly · 2006

AzodicarbonamideInpharma Weekly · 1999

Recommendations for treatment of severe aplastic anaemiaInpharma Weekly · 1994

Did you know about R&D costs?Inpharma Weekly · 1993

R&D investment in JapanInpharma Weekly · 1993

NICE creates new R&D committeeInpharma Weekly · 2003

Gallic acid has potential in lung cancerInpharma Weekly · 2002

New mesalazine formulation advantageous in IBDInpharma Weekly · 2001